{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaubsepzmt3pyfpjokgncrbqo2bdd7vpiz53jssi7bz6idlnxymaq",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3minkx4zkatn2"
  },
  "path": "/t/thinking-clearly-about-association-studies-risk-factors-and-causal-salad-included/28679#post_20",
  "publishedAt": "2026-04-03T13:26:24.000Z",
  "site": "https://discourse.datamethods.org",
  "textContent": "For the example I gave, worth noting: **Tazverik (tazemetostat) was voluntarily withdrawn from all global markets and indications on March 9, 2026, due to safety concerns.** For dire indications with no effect therapy, arguably best supportive care can be a control that will be acceptable to some patients and to IRB reviewers.",
  "title": "Thinking Clearly about Association Studies (Risk Factors and Causal Salad included)"
}